AR115014A1 - ANTIBODIES AGAINST MICA AND / OR MICB AND ITS USES - Google Patents
ANTIBODIES AGAINST MICA AND / OR MICB AND ITS USESInfo
- Publication number
- AR115014A1 AR115014A1 ARP190100743A ARP190100743A AR115014A1 AR 115014 A1 AR115014 A1 AR 115014A1 AR P190100743 A ARP190100743 A AR P190100743A AR P190100743 A ARP190100743 A AR P190100743A AR 115014 A1 AR115014 A1 AR 115014A1
- Authority
- AR
- Argentina
- Prior art keywords
- mica
- cdr3
- micb
- cdr2
- polypeptide
- Prior art date
Links
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 title abstract 2
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 title abstract 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 102000043129 MHC class I family Human genes 0.000 abstract 2
- 108091054437 MHC class I family Proteins 0.000 abstract 2
- 229910052618 mica group Inorganic materials 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108010031034 MHC class I-related chain A Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000010445 mica Substances 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Anticuerpos que se fijan a MICA/B humano y métodos para usarlos. También métodos para tratar un tipo de cáncer en un sujeto, que comprende administrar al sujeto un anticuerpo anti-MICA/B. Reivindicación 1: Un anticuerpo que se fija de manera específica a la secuencia A relacionada con el polipéptido de MHC de clase I humano (MICA) y/o la secuencia B relacionada con el polipéptido de MHC de clase I humano (MICB), caracterizado porque comprende una región variable de la cadena pesada (VH) y a región variable de la cadena liviana (VL); en donde la VH comprende a región determinante de la complementariedad (CDR) de la VH 1, una VH-CDR2 y una VH-CDR3 y la VL comprende una VL-CDR1, una VL-CDR2 y una VL-CDR3; en donde la VH-CDR3 comprende una secuencia de aminoácidos seleccionada del grupo que consiste en SEQ ID Nº 7, 17, 27, 37 y 47.Antibodies that bind to human MICA / B and methods of using them. Also methods of treating a type of cancer in a subject, comprising administering an anti-MICA / B antibody to the subject. Claim 1: An antibody that specifically binds to sequence A related to human MHC class I polypeptide (MICA) and / or sequence B related to human MHC class I polypeptide (MICB), characterized in that comprises a variable region of the heavy chain (VH) and a variable region of the light chain (VL); wherein the VH comprises a VH 1 complementarity determining region (CDR), a VH-CDR2 and a VH-CDR3 and the VL comprises a VL-CDR1, a VL-CDR2 and a VL-CDR3; wherein VH-CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID Nos. 7, 17, 27, 37 and 47.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862647566P | 2018-03-23 | 2018-03-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115014A1 true AR115014A1 (en) | 2020-11-18 |
Family
ID=73543366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190100743A AR115014A1 (en) | 2018-03-23 | 2019-03-22 | ANTIBODIES AGAINST MICA AND / OR MICB AND ITS USES |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR115014A1 (en) |
-
2019
- 2019-03-22 AR ARP190100743A patent/AR115014A1/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126242A2 (en) | CANCER TREATMENT USING CHIMERIC ANTIGEN RECEPTORS | |
| PE20210665A1 (en) | ANTIBODIES AGAINST MICA AND / OR MICB AND ITS USES | |
| CL2019001926A1 (en) | Anti-tigit antibodies and antigen-binding fragments; pharmaceutical composition comprising them; polynenucleotide encoding said antibody; vector comprising them, host cell; method of producing said antibody or antigen-binding fragment thereof; and use in the treatment of cancer. (Divisional Application 310-2017). | |
| PE20220495A1 (en) | CHIMERIC ANTIGENIC RECEPTORS AND BINDING AGENTS TARGETING DLL3 | |
| AR110979A1 (en) | CD70 BINDING MOLECULES AND SAME USE METHODS | |
| AR096617A1 (en) | ANTI-TWEAKR ANTIBODIES AND THEIR USES | |
| PE20171654A1 (en) | COMPOSITIONS AND METHODS USED TO INCREASE IMMUNE RESPONSE AND IN CANCER THERAPY | |
| PE20191463A1 (en) | BISPECIFIC ANTIBODIES OF SPECIFIC JOINT PD1 AND LAG3 | |
| SA519410565B1 (en) | Novel Monoclonal Antibodies to Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) | |
| AR084141A1 (en) | ANTI-CCL20 NEUTRALIZING ANTIBODIES | |
| PE20191079A1 (en) | IMMUNOGLOBULINS AND USES OF THEM | |
| PE20121649A1 (en) | MONOCLONAL ANTIBODIES TO PROGASTRIN AND ITS USES | |
| AR110017A1 (en) | PD-1 ANTIBODIES AND USES OF THESE | |
| AR101829A1 (en) | CANCER TREATMENT USING A CLL-1 CHEMERIC ANTIGEN RECEIVER | |
| AR111830A1 (en) | MONOCLONAL ANTI-BODIES ANTAGONISTS AGAINST CD40 AND ITS USES | |
| PE20211291A1 (en) | ANTI-OX40 ANTIBODIES AND METHODS OF USE | |
| PE20221263A1 (en) | ILT3 BINDING AGENTS AND METHODS OF USE THEREOF | |
| PE20120475A1 (en) | SPECIFIC ANTIBODIES FOR DKK-1 | |
| PE20181270A1 (en) | ANTIBODY THAT NEUTRALIZES THE HUMAN SYNCITIAL RESPIRATORY VIRUS | |
| AR075504A1 (en) | MOLECULES OF ANTIBODIES THAT HAVE SPECIFICITY FOR THE HUMAN OX40 | |
| ES2687282T3 (en) | ANTI-CD134 (OX40) humanized antibodies and their uses | |
| AR099812A1 (en) | ANTI-EGFR ANTIBODY AND DRUG ANTIBODIES AND CONJUGATES | |
| PE20050712A1 (en) | RG1 ANTIBODIES | |
| PE20110225A1 (en) | COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING COMPLEMENT PROTEIN C5 | |
| PE20201171A1 (en) | HEAVY CHAIN ANTIBODIES JOINING CD22 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |